GLP-1 Medications with a simple generic name of "semaglutide", "liraglutide", "tirzepatide", "dulaglutide", "exenatide", "exenatide microspheres", or "insulin degludec/liraglutide" and at least one of: A pharmaceutical class of "ANTI-OBESITY GLUCAGON-LIKE PEPTIDE-1 RECEP AGONIST" or "ANTIHYPERGLYCEMIC - INCRETIN MIMETICS COMBINATION" A pharmaceutical class that contains "GLP-1" A pharmaceutical subclass that contains the text "GLP-1"
IV and injection therapy are commonly used to support energy, hydration, immune health, recovery, and overall wellness
Real-Life Situation : Employees demand coverage for popular GLP-1 medications, but high utilization leads to increased premiums or benefit cuts in other areas
As a worked example for concentration planning, reconstituting a 50 mg vial with 5 mL of bacteriostatic water yields a 10 mg/mL stock
10mg vial at 100mcg/dose (starting) = 100 doses 10mg vial at 250mcg/dose (standard) = 40 doses 10mg vial at 500mcg/dose (higher end) = 20 doses At 250mcg daily, a 10mg vial would theoretically last 40 days but since reconstituted peptide should be used within 28 days, plan to start a new vial after 4 weeks regardless of remaining volume
Look for practitioners who have successfully completed the Functional Medicine University's Certification Program (CFMP) www.functionalmedicinedoctors.com